Equillium’s $70 Million IPO Expected This Week for Immuno-Inflammatory Diseases Lead candidate targeting graft-versus-host disease (GvHD) (Image: Equillium). 4 MIN READ 10.9.2018
Biotech’s Cancer Investing Highlights: October 1-5 Highlights from the week in cancer research that may be important for investors in the biotech space 4 MIN READ 10.8.2018
Geron Announces Termination of Janssen Collaboration in Blood Cancer Geron regains global rights to the imetelstat program and will focus on initiating Phase 3 studies (Image: Geron) 4 MIN READ 09.27.2018
Geron’s Imetelstat Reaffirmed as a Priority for Johnson & Johnson JNJ CEO Alex Gorsky cites hematology-related oncology among "key catalysts for growth." 4 MIN READ 07.18.2018
Geron Presents Positive Phase 2/3 Data on Blood Cancer Therapy 34% of patients achieved red blood cell transfusion independence lasting at least 8 weeks. 4 MIN READ 06.18.2018
Biotech Investors Should Look For Turnaround Opportunities The biotech bull market is not over. That's the judgment of Reni Benjamin of H.C. Wainwright & Co., who predicts high quality data from a broad range of small- and mid-cap biotechs will 21 MIN READ 07.17.2014
